TRIMTECH Therapeutics

TRIMTECH Therapeutics is a biotech company focused on harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases. The company is developing treatments for severe neurodegenerative and inflammatory disorders like Alzheimer's and Huntington's disease, using its aggregate-selective degrader molecules known as TRIMTACs to degrade protein aggregates associated with diseases.

Funding Round: Seed

Funding Amount: $31M

Date: 05-Mar-2025

Investors: Cambridge Innovation Capital (CIC), SV Health Investors’ Dementia Discovery Fund (DDF), M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, Start Codon

Markets: Biotech, Therapeutics, Healthcare

HQ: Cambridge, England, United Kingdom

Founded: 2023

Website: https://trimtechtherapeutics.com/

LinkedIn: https://www.linkedin.com/company/trimtech-therapeutics-limited

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/trimtech-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/679261-69